skip-to-main

Spikevax (previously COVID‑19 Vaccine Moderna)

A Conditional Marketing Authorisation (CMA) has been granted in the EU and UK for Spikevax (previously COVID‑19 Vaccine Moderna) to prevent coronavirus disease 2019 (COVID‑19) in people from 12 years of age.

Great Britain
Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Dear Healthcare Professional

Dear Healthcare Professional

Northern Ireland
Patient Information Leaflet

Patient Information Leaflet

Summary of Product Characteristics

Summary of Product Characteristics

Dear Healthcare Professional

Dear Healthcare Professional

Contact Moderna

8am-5pm GMT – Mon - Fri
EMEAMedinfo@modernatx.com